|
IIII � iii IIII eaiii IIII��ty by III IIIIa iin C o s� P 111Y 8 C)
<br />HIU ,
<br />Number of
<br />A,vuo-raguu Paid
<br />Utl Ill;ci,n'g
<br />Number of
<br />.alculated
<br />Amount pour R:udud Amount par
<br />Average Dai",
<br />Drug Label Name
<br />Members
<br />Claims
<br />In ruu ilomtl d *sl
<br />N"Md Annuauan t
<br />C laiimn UtHilzing
<br />Member
<br />supp4y
<br />E,N BkE1L SRCLK
<br />1
<br />12:
<br />$61 270
<br />S60.0117
<br />$5K005.1.$6
<br />$M,30 0
<br />28.0
<br />VICT07A
<br />12
<br />46
<br />$6n,471
<br />S59,01R
<br />$11,283.371
<br />$4,518
<br />49.31
<br />TRUIIUc,,,r$1"
<br />r05'
<br />$riu.953
<br />S56,816
<br />$3748(i
<br />$+k; 535
<br />3F.t3
<br />INVCYKANJA
<br />19
<br />71
<br />$SRI, 75
<br />$5C,I51$R
<br />57%.31
<br />i$.4,3r4�,)
<br />517
<br />(,LUMETZA
<br />1
<br />3,
<br />$U,641
<br />SSr,.231
<br />$11,4,25.136
<br />$52,281
<br />90.0
<br />Fl t.I1"af:INONIDF,
<br />43
<br />110
<br />$,47.,060
<br />$e1,C3,8011
<br />$11,170.02'.
<br />$.2,4,Rl
<br />2&D
<br />ZYTIGA
<br />1
<br />5
<br />$45023
<br />S45,034)
<br />$9,11C)57l
<br />$45,4030
<br />30.0
<br />HU'MIRA
<br />1
<br />7'
<br />$35„7511
<br />S35,051
<br />$5,007.29
<br />$15,051
<br />213.0
<br />1"EC1F1DER A
<br />1
<br />$,341,016
<br />2$,13R8
<br />$`14,9194.25
<br />$2,9,988
<br />50A
<br />ROSUVr' FSTA;TIN
<br />4$I
<br />237
<br />$2,13 k3,6.,"2
<br />524,64.2
<br />$102.98
<br />$536
<br />4TO
<br />FARXIGA
<br />R
<br />40,
<br />W 6263
<br />S24.080
<br />002.01
<br />$3,0130
<br />43.5
<br />GR,AUSE
<br />�4
<br />LE
<br />$24„829
<br />$23,55,6
<br />5 V,'192.79
<br />$5,M,
<br />51.0
<br />;1ANUVI,A
<br />1
<br />M
<br />$24,197
<br />523,,414
<br />$755„v
<br />$3,345
<br />55,2
<br />GUPIIXEINT
<br />1
<br />3
<br />$23„550
<br />$23,110
<br />$2,880.75
<br />$2:3„410
<br />26.3
<br />1,,,;YIRI A
<br />1II
<br />3
<br />$r23 +46
<br />23,061;9
<br />$13$;'9 4 u
<br />7
<br />353
<br />ANDROGEL
<br />dt
<br />22.
<br />$22,778
<br />$22,415
<br />$11,1010..135
<br />$5,604
<br />25.3
<br />ATCARVA TATIN
<br />6
<br />274,
<br />$24,1500
<br />S22„32'.3
<br />S$147
<br />$1343
<br />571
<br />'wYVANSE
<br />45
<br />55
<br />'$23„729
<br />$22,144
<br />$320.93
<br />$1,475
<br />34.4
<br />10FTFORtt41N
<br />65
<br />302
<br />V31102
<br />,,1,454
<br />S+7`1 T14-
<br />5330
<br />51,L)5
<br />0MIEPRA7"13MC;AR
<br />3
<br />10
<br />'$20,993
<br />$20,945.
<br />$2,094.+46,
<br />$6„902
<br />30.0
<br />,NANUMFT„KR
<br />18
<br />22
<br />$231778
<br />514,5102
<br />$90463
<br />5'3,317
<br />655
<br />DEXIILAN,1"
<br />tt2
<br />61
<br />$21,356
<br />$119,71.5
<br />$323.210�,
<br />$1.,&13
<br />38.,9
<br />QT 21A
<br />1
<br />5'
<br />$19,06
<br />S45,637t3
<br />53�278,20
<br />Sa114,67$
<br />300
<br />DU'EKIS
<br />7
<br />S
<br />$1D,760
<br />S19.471
<br />$2.163.41
<br />$2„772
<br />27.0
<br />DOXFPIN F1T:91.,
<br />tit
<br />31I
<br />$1R 2:3,.,
<br />SrIR,C*2
<br />$S13'1 $37'
<br />$1,,:;03
<br />217
<br />F:ORIE,0
<br />1
<br />5
<br />$17,416
<br />S16,915,'
<br />$3,383.116
<br />$1Si'„30163
<br />28.0
<br />CIiAlgS
<br />12
<br />4$1
<br />$17„7$1$S
<br />$11a1618
<br />$.$61„26,
<br />51,$RSi
<br />24,3
<br />GLA141Iw.AMLR
<br />'1
<br />1
<br />$1bS14a
<br />$1L,515
<br />$16,515 35
<br />$1'5,5''I':'°�
<br />84.0
<br />ADVAR D1;5KUI
<br />9
<br />32
<br />$514.67
<br />!$,1,0�90
<br />4,1.3
<br />LAM IC: I"AL;11R
<br />1
<br />11
<br />$14,744
<br />S16.0W
<br />$41,413'3.40
<br />$15.301:17
<br />30.0
<br />"1"r't, 30 DrUN$S'roi.. l
<br />INd,+'A.
<br />1,525'
<br />S902,449
<br />$H,T4,45✓5
<br />$5,7:3.41
<br />WA
<br />45A
<br />Talal All C4lalimy
<br />842
<br />12,751
<br />$1 4$`a2, H
<br />51,824,795
<br />$14.3..0$
<br />U,247
<br />34..E
<br />I hese are comprised mostly of Specialty drug classifications
<br />19 1 , 1itJI�11l 11oliollI I'lled
<br />
|